Q-omics provides the consensus-scored GUSBP1 profile across patient tissues and cancer cell-line models. GUSBP1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, GUSBP1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, GUSBP1 RNA expression shows 20,553 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, HNSC, and UVM as cancer lineages where GUSBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUSBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUSBP1 survival associations across molecular data types. GUSBP1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUSBP1 RNA expression–survival associations across cancer types. High GUSBP1 expression shows unfavorable associations in ACC, UCEC, KICH, LIHC and MESO, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for GUSBP1 RNA expression.
This table summarizes GUSBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for GUSBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUSBP1 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, KIRC, CHOL and LUSC. The HNSC box plot shows higher GUSBP1 RNA expression in tumor versus normal tissue (log2 FC = +0.592, t-test p < 0.001).
This table shows molecular features associated with GUSBP1 in patient tissues and cancer cell lines. In patient samples, GUSBP1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GUSBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD.
